The estimated Net Worth of Biopharma Partners Ii Lpalt... is at least $6.41 Milhão dollars as of 16 October 2009. Biopharma Lpalt owns over 349,651 units of Corcept Therapeutics Inc stock worth over $6,406,252 and over the last 15 years Biopharma sold CORT stock worth over $0.
Biopharma has made over 1 trades of the Corcept Therapeutics Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Biopharma bought 349,651 units of CORT stock worth $482,518 on 16 October 2009.
The largest trade Biopharma's ever made was buying 349,651 units of Corcept Therapeutics Inc stock on 16 October 2009 worth over $482,518. On average, Biopharma trades about 349,651 units every 0 days since 2009. As of 16 October 2009 Biopharma still owns at least 180,204 units of Corcept Therapeutics Inc stock.
You can see the complete history of Biopharma Lpalt stock trades at the bottom of the page.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson, eVentures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: